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ORIGINAL ARTICLE
Background/Aims: Acute myocardial infarction (AMI) is a leading cause of death. Inflammatory processes play
an important role in atherosclerosis, which is intimately related to AMI. The aim of this study was to investigate the
association between anti-inflammatory and pro-inflammatory cytokines ratios and AMI.
Methods: A total of 90 AMI patients and 90 age-and sex-matched controls were recruited in this study. Plasma
cytokines and conventional risk factors were determined by standard methods.
Results: Patients with AMI showed increased interleukin (IL)-6 and tumor necrosis factor-α levels and lower anti-
to pro-inflammatory cytokine ratios as compared with controls. A multivariate logistic regression analysis revealed
that IL-10 to IL-6 ratio was independently associated with the occurrence of AMI (odds ratio [OR], 5.39; 95%
confidence interval [CI], 2.39 to 12.17; p < 0.0001). In contrast, IL-6 levels were no longer significant in the
multivariate model (OR, 1.02; 95% CI, 0.932 to 1.12; p = 0.603). A receiver operating characteristic (ROC) curve
analysis indicated that IL-6 levels and IL-10 to IL-6 ratios were a significant predictor of AMI (area under ROC
curve, 0.892 and 0.851, respectively).
Conclusions: Our results suggest that the ratio of IL-10 to IL-6 is independently associated with AMI, and reduced
levels of this ratio may favor the development of AMI. (Korean J Intern Med 2010;25:44-50)
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INTRODUCTION
Acute myocardial infarction (AMI) is a multi-factorial
disease. AMI is often caused by unstable plaque in the
epicardial coronary artery, in which inflammatory processes
play a central role [1]. In this regard, several circulating
pro-inflammatory molecules have been associated with
thrombotic cardiovascular events including acute phase
proteins, cellular adhesion molecules, and cytokines [2].
Moreover, few articles have explored the predictive value
of inflammatory markers on cardiovascular events in
cardiovascular disease-free subjects [3,4]. Far fewer studies
have considered multiple markers, such as interleukin
(IL)-6, tumor necrosis factor-α (TNF-α), and IL-10
simultaneously. In fact, most studies have focused only on
C-reactive protein (CRP) [5]. A recent longitudinal study
demonstrated a stronger role for IL-6 in the prediction of
congestive heart failure, as compared with CRP [3].
Animal experiments suggest that IL-6 and TNF-α play
important roles in the regulation of acute phase protein
synthesis. Acute phase proteins, such as fibrinogen and
factor VIII, are established risk factors for atherosclerosis
[6]. The plasma cytokine IL-6 plays an important role in
mediating inflammation and is a central stimulus for the
acute phase response [7].
The effects of inflammatory stimuli are counterbalanced
by anti-inflammatory mechanisms, including IL-10, IL-4,
high-density lipoproteins (HDL), and vascular endothelialBiswas S, et al. Anti- to pro-inflammatory cytokine ratios in acute myocardial infarction    45
growth factor [8,9]. IL-10 is a centrally operating anti-
inflammatory cytokine that plays a crucial role in the
regulation of the innate immune system. Studies using IL-
10 deficient mice have shown that IL-10 has a protective
role in atherosclerosis [10]. Further, it strongly deactivates
the inflammatory host response and potently inhibits the
production of pro-inflammatory cytokines [11].
The present study was performed to investigate the




The study population was composed of individuals from
the eastern part of India of Asian-Indian origin with a
history suggestive of AMI. All cases (n = 90) were evaluated
using electrocardiographic (ECG) criteria, cardiac enzyme
studies, and echocardiographic evaluation (evidence of
regional wall motion abnormalities and left ventricular
ejection fraction > 50%). All recruited patients were
admitted within 12 hours after the first episode of chest
pain. Healthy age- and sex-matched controls (n = 90)
included subjects without any of the following
characteristics: signs of ischemic heart disease, ECG
criteria suggestive of acute coronary syndrome, or a past
history of cardiovascular disease and diabetes. Samples
were obtained from consecutively examined patients
except for those with the following exclusion criteria:
patients taking known lipid altering medications; use of
non-steroidal, antiinflammatory drugs; and the presence
of chronic kidney disease. All patients were admitted to
the hospital within 12 hours of the onset of chest pain.
Blood samples for cytokine and biochemical analysis were
taken at the time of admission. Blood samples were
collected by vein puncture into vacuum tubes containing
EDTA. Plasma samples were processed and divided into
aliquots and stored in cryovials at -70o˚C until further
analysis for cytokines.
The demographic characteristics of patients and control
subjects are shown in Table 1. The subjects of the present
study were part of a health examination between the
Immunotechnology Section (presently Division of
Molecular Medicine), Bose Institute Kolkata, and the
Department of Cardiology, NRS Medical College and
Hospital, Kolkata. Participants between 45 and 65 years
of age were recruited between November 2006 and
September 2007. The institutional ethics committee
approved the study protocol.
Blood biochemistry
Detailed self-reported questionnaires containing
information on the history of hypertension, smoking
status, and alcohol consumption were collected at baseline
and used for analysis. Waist circumferences were also
measured according to standard methods. The following
parameters were measured using standard methods in
our laboratory: glucose, total cholesterol, and HDL
cholesterol (HDL-C). Low-density lipoprotein cholesterol
(LDL-C) levels were calculated using the Friedewald
equation [12] and non-HDL-C levels were calculated as
follows: Non-HDL-C = Total cholesterol - HDL-C.
IL-6, TNF-α, and IL-10 levels were measured from
frozen stored plasma. Cytokines were measured in
duplicate using an enzyme-linked immunosorbance assay
kit from Diaclone Research, Besancon, France. These
assay kits had a lower limit of detection of 8 pg/mL for
TNF-α, 2 pg/mL for IL-6, and 5 pg/mL for IL-10.
Table 1. Characteristic of Asian Indian population in Eastern part of India in the case and control group
Variable Case (n = 90) Control (n = 90) p value
Age, yr 52.99 ± 9.31 51.79 ± 9.10 matched
Sex matched
Male 81 (90) 81 (90)
Female 9 (10) 9 (10)
Smoking 64 (71.1) 17 (18.8) < 0.0001
Hypertension 58 (64.4) 5 (5.5) < 0.0001
Alcohol 24 (26.7) 7 (7.8) < 0.0001
Waist circumference, cm 87.16 (6.29) 85.48 (5.5) 0.054
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Statistical analysis
Results are presented as the means ± SD and the
percentage of the population studied. Student’s t tests and
Mann-Whitney U tests were used to examine differences
between the two groups. For determination of optimal
cut-off values and diagnostic performance of these
continuous variables, receiver operating characteristic
curves analysis was performed. Optimal cut-off points
for these risk factors were determined based on the
convergence of sensitivity and specificity. Stepwise logistic
regression analysis was used to assess the independent
adjusted relationship between different variables and AMI
with independent variables being those with p ≤ 0.05 in
univariate analysis. All statistical tests were two-sided. A
pvalue < 0.05 was considered to be statistically significant.
SPSS (SPSS Inc., Chicago, IL, USA) was used for all
calculations and MedCalc
® version 9.2.0.1 statistical
software (MedCalc Software, Mariakerke, Belgium) was
used only for comparison between areas under receiver
operating characteristic curves of different variables.
RESULTS
General characteristics of the study subjects
Baseline characteristics of study participants are shown
Table 2. The demographic information in AMI group and control groups
Variables  AMI (n = 90) Control (n = 90) p valuea
IL-10, pg/mL 38.8 ± 12.1 40.0 ± 15.1 0.552
IL-6, pg/mL 16.1 ± 10.3 7.5 ± 4.4 < 0.0001
TNF-α, pg/mL 54.9 ± 17.2 46.6 ± 14.3 0.001
IL-10/IL-6 3.0 ± 1.3 6.3 ± 3.2 < 0.0001
IL-10/TNF-α 0.8 ± 0.3 0.9 ± 0.3 0.002
Glucose, mg/dL 92.1 ± 31.0 77.9 ± 14.2 < 0.0001
Total cholesterol, mg/dL 195.3 ± 39.3 156.8 ± 32.9 < 0.0001
LDL-C, mg/dL 126.3 ± 32.9 93.8 ± 29.3 < 0.0001
HDL-C, mg/dL 29.4 ± 6.8 33.8 ± 7.9 < 0.0001
TG, mg/dL 197.5 ± 60.0 146.3 ± 56.2 < 0.0001
Non-HDL-C, mg/dL 165.8 ± 37.3 123.0 ± 34.6 < 0.0001
Values are presented as mean ± SD.
aNon-paired student's t-test for comparisons between case and control group.
AMI, acute myocardial infarction; IL, interleukin; TNF-α, tumor necrosis factor-alpha; LDL-C, low density lipoprotein cholesterol; HDL-C, high
density lipoprotein cholesterol; TG, triglyceride.
Table 3. Area under the receiver operating characteristic curve and optimal cut off values of different variables
Variables AUC p value Optimal cut-off Sensitivity Specificity
IL-10, pg/mL 0.518 0.671 66.35 0.978 0.114
IL-6, pg/mL 0.892 < 0.0001 8.85 0.911 0.795
TNF-α, pg/mL 0.644 0.001 45.20 0.778 0.568
IL-10/IL-6 0.851 < 0.0001 4.45 0.889 0.682
IL-10/TNF-α 0.625 0.004 0.70 0.489 0.772
Glucose, mg/dL 0.632 0.002 85.00 0.467 0.841
Total cholesterol, mg/dL 0.802 < 0.0001 167.00 0.822 0.750
LDL-C, mg/dL 0.793 < 0.0001 102.00 0.800 0.705
HDL-C, mg/dL 0.681 < 0.0001 30.00 0.600 0.841
TG, mg/dL 0.757 < 0.0001 169.00 0.756 0.682
Non-HDL-C, mg/dL 0.830 < 0.0001 138.00 0.844 0.772
AUC, area under the curve; IL, interleukin; TNF-α, tumor necrosis factor-alpha; LDL-C, low density lipoprotein cholesterol; HDL-C, high density
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in Table 1. Among these study participants, 90 AMI
patients (81 males [90%] and 9 females [10%]) and 90
age-and sex-matched healthy controls (81 males [90%]
and 9 females [10%]) were recruited. Individuals who
suffered from AMI were more likely to smoke, drink
alcohol, suffer hypertension, and have a higher mean waist
circumference as compared with healthy controls.
Study population characteristics were compared with
controls (Table 2). AMI patients had lower levels of HDL-C
and IL-10, and higher fasting glucose, triglyceride, LDL-C,
non-HDL-C, total cholesterol, and plasma levels of IL-6
and TNF-α as compared with control. Furthermore, the
ratio of IL-10 to IL-6 and the ratio of IL-10 to TNF-α were
both lower in AMI patients as compared with the control
group.
Cytokines
Mean concentrations of anti-inflammatory cytokine IL-
10 were lower in the AMI group as compared with the
control group; however, this difference was not significant
(38.81 vs. 40.03 pg/mL, p = 0.552, Table 2). AMI patients
had significantly higher plasma concentrations of the
pro-inflammatory cytokines IL-6 and TNF-α as compared
with controls (IL-6 concentration, 16.10 ± 10.32 vs. 7.52 ±
4.36 pg/mL; p < 0.0001), (TNF-α concentration, 54.94 ±
17.19 vs. 46.61 ± 14.33 pg/mL; p = 0.001). No significant
differences in anti-inflammatory cytokine values were
observed; however, the anti-to pro-inflammatory cytokine
ratio was significantly lower in AMI patients as compared
with controls ([IL-10 to IL-6 ratio, 2.96 ± 1.31 vs. 6.31 ± 3;
p < 0.0001], [IL-10 to TNF-α ratio, 0.76 ± 0.29 vs. 0.91 ±
0.34; p = 0.002]).
ROC analysis
For discrimination between patients and controls,
we found that the area under the receiver operating
characteristic (ROC) curve ranged from 0.518 to 0.892
(Table 3). As shown in Table 3, IL-6 (area under the curve
[AUC], 0.892; p < 0.0001), IL-10 to IL-6 ratios (AUC,
0.851; p < 0.0001), and non-HDL-C (AUC, 0.830; p <
0.0001) showed superior performance against other
parameters. IL-6 had the highest area under the curve;
Table 4. Univariate logistic regression analysis
Variables Odds ratio  95% confidence interval p value
IL-10, pg/mL 1.00 0.985 - 1.02 0.550
IL-6, pg/mL 1.38 1.23 - 1.55 < 0.0001
TNF-α, pg/mL 1.03 1.01 - 1.05 0.001
IL-10/IL-6 2.26 1.75 - 2.91 < 0.0001
IL-10/TNF-α 4.68 1.73 - 12.62 0.002
Glucose, mg/dL 1.02 1.01 - 1.04 0.004
Total cholesterol, mg/dL 1.03 1.02 - 1.04 < 0.0001
LDL-C, mg/dL 1.03 1.02 - 1.05 < 0.0001
HDL-C, mg/dL 1.08 1.03 - 1.14 0.0004
TG, mg/dL 1.02 1.01 - 1.03 < 0.0001
Non-HDL-C, mg/dL 1.03 1.02 - 1.04 < 0.0001
Waist circumference, cm 1.05 1.00 - 1.10 0.056
IL, interleukin; TNF-α, tumor necrosis factor-alpha; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG,
triglyceride.
Table 5. Multivariate logistic regression analysis
Variables Odds ratio 95% confidence interval p value
TNF-α 1.18 1.08 - 1.30 0.0001
IL-10/IL-6 5.39 2.39 - 12.17 < 0.0001
IL-10/TNF-α 2.55 0.147 - 4.42 0.001
LDL-C 1.06 1.00 - 1.13 0.019
Non-HDL-C 1.10 1.04 - 1.16 0.0002
TNF-α, tumor necrosis factor-alpha; IL, interleukin; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.48 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
however, this value was not significantly higher than the
area under the curve for the IL-10 to IL-6 ratio (difference,
0.041; p = 0.069) or non-HDL-C (difference, 0.062; p =
0.111). The area for the IL-10 to IL-6 ratio, which is a
balance between anti- and pro-inflammatory cytokine,
was slightly larger than the area for non-HDL-C (difference,
0.021; p = 0.615). This analysis demonstrates that IL-6
shows superior performance against the other parameters
in our study population. IL-6 concentrations at an optimal
cut-off level of 8.85 pg/mL showed a sensitivity and
specificity of 91% and 79%, respectively (Table 3).
Diagnostic performance and sensitivity and specificity
values for other parameters are also shown in Table 3.
Logistic regression analysis
In the univariate logistic regression analysis we found
that the ratios of IL-10 to TNF-αand IL-10 to IL-6 showed
greater odds ratios than the other variables (Table 4). To
further delineate a potential independent association
between IL-6 and TNF-α, a multivariate analysis was
performed, which included the ratio of anti-to pro-
inflammatory cytokines markers; baseline characteristics,
which showed significant discriminating abilities in the
ROC curve analysis; and independent variables found in
the univariate analysis. Anti-to pro-inflammatory cytokine
ratios, TNF-α, LDL-C, and non-HDL-C remained significant.
IL-6 was no longer significant (Table 5) after the IL-10 to
IL-6 ratio was introduced into the model (odds ratio, 1.38;
p < 0.0001 without IL-10 to IL-6 ratio).
DISCUSSION
The assessment of inflammatory markers as additional
risk factors in the evaluation of cardiovascular events
should be encouraged. Further studies are necessary to
determine whether inflammatory markers may represent
valid targets for new medications that can be used to slow
the atherosclerosis process. Plasma concentrations of
cytokines in virtually all of the subjects tested was deter-
mined, and it was found that a variety of phenomena were
associated with changes in plasma cytokines. In our study,
IL-10 to IL-6 cytokines ratios showed more consistent
results than any other cytokines.
IL-6 and TNF-αare known to influence lipid metabolism
in animals via two separate mechanisms [13,14]. First,
these cytokines stimulate fatty acid synthesis by the liver
and secondly, TNF-α stimulates lipolysis by adipocytes.
These changes may explain the association between
cytokines and plasma triglyceride. The observation that
alcohol consumption is associated with reduced TNF-α is
consistent with studies that have shown suppression of
TNF-α production by macrophages with alcohol con-
sumption [6]. The association of alcohol with reduced
plasma TNF-α may explain the relationship between
alcohol and increased HDL-C concentrations.
Circulating IL-6 concentrations may be the result of a
variety of stimuli, including various clinical risk factors
that lead to the release of IL-6 from numerous cell types,
including smooth muscle cells and macrophage/foam
cells found in atheromatous plaques [15]. IL-6 can be
released from adipocytes and may stimulate a response
from the hypothalamic pituitary-adrenal axis, resulting in
hypertension and obesity [16]. In this study we also found
that increased IL-6 levels are associated with hyper-
tension. Consistent with previous studies [17], we found
that circulating levels of IL-6 were increased in obese
patients as compared with lean patients. Prior studies of
AMI suggest that cytokines are preferentially produced by
inflammatory cells in the pre-infarct zone, and persistent
elevation of cytokines results from an increased infiltration
of inflammatory cells [18]. In our study, individuals with
elevated levels of TNF-α were at an increased risk for AMI.
Thus, these data are consistent with the hypothesis that
inflammation plays a major role in atherosclerosis [19].
Less information is available regarding the role of anti-
inflammatory cytokines in AMI. It recently has been
demonstrated that the anti-inflammatory cytokine IL-10
may act as a protective factor in atherosclerosis. IL-10 is
expressed in both early and advanced human athero-
sclerotic plaques [20] and inhibits many cellular processes
including metalloproteinase production and tissue factor
expression, which may play a role in the clinical expression
of atherosclerotic plaque rupture or erosion. IL-10 con-
centrations were particularly low in the AMI study group.
IL-10 is a powerful suppressor of the immune response,
and is produced by T-cells, B cells, monocytes, and
macrophages [11,21]. IL-10 inhibits pro-inflammatory
cytokines such as TNF-αand IL-6 [11] and has multifaceted
anti-inflammatory properties, including inhibition of
prototypic pro-inflammatory transcription factors, i.e.,
nuclear factor κB, which leads to the suppression of
cytokine production [22]. IL-10 is expressed in advanced
human atherosclerosis and is associated with low inducible
nitric oxide synthase expression and low levels of apoptosis
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are lower in AMI patients; however, this difference is not
statistically significant as compared with the control
group. This result suggests that decreased plasma IL-10
concentrations are associated with clinical instability. Pro-
inflammatory cytokine (IL-6 and TNF-α) plasma
concentrations were significantly higher in AMI patients
as compared with controls. In contrast, lower plasma
concentrations of the anti-inflammatory cytokine IL-10
were found in the AMI group as compared with controls;
however, this difference was not statistically significant.
The beneficial effects of elevated IL-10 plasma levels were
restricted to patients with elevated IL-6 and TNF-α
plasma levels, which is an indication of an enhanced
systemic inflammatory response. These data support the
hypothesis that the balance between anti-inflammatory
and pro-inflammatory cytokines may reflect the intensity
of occult plaque inflammation and vulnerability to rupture
[24,25]. Therefore, we examined anti- and pro-inflammatory
cytokine ratios and found that IL-10 to IL-6 ratios were
strongly associated with AMI. A low IL-10 to TNF-α ratio
is associated with severe malarial anemia, and an insuffi-
cient IL-10 response to high TNF-α concentrations may
have had a central role in the progression of this disease
[26].
Limitations of previous studies on cytokine markers in
AMI include the inclusion of only one or two cytokines
that are pro-inflammatory or anti-inflammatory. Multiple
cytokines are involved in the inflammatory process, and
have overlapping, antagonistic, and synergetic effects on
many cell types. In addition, they up-and down-regulate
the production of other cytokines and inflammatory
markers. In our study, we included two pro-inflammatory
cytokines and one anti-inflammatory cytokine. The
limitation of the present study is the lack of follow-up
data, mostly due to the lack of patient compliance. This
additional data may have provided important information
about anti- to pro-inflammatory cytokine ratios as markers
for risk stratification and prognosis.
In conclusion, inflammation and thrombosis are inter-
connected pathologies in the natural history of athero-
sclerosis and measurements of inflammatory markers
may aid in predicting the prognosis of patients with AMI.
IL-10 to IL-6 ratios and IL-6 measurements were
equivalent in their ability to discriminate between persons
with and without AMI. Data from the multivariate model,
however, suggest that the IL-10 to IL-6 ratio is associated
with AMI, whereas IL-6 levels are not. Thus, our data
suggest that the IL-10 to IL-6 ratio, and not IL-6 levels,
may be a valuable indicator of AMI. Our results also suggest
that reduced anti- to pro-inflammatory cytokine ratios
may favor atheromatous plaque instability and may be
implicated in the development of AMI.
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